Estrogen receptor β selective nonsteroidal estrogens: Seeking clinical indications

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 4, 2010, Pages 507-534

  Mohler, Michael L ^a   Narayanan, Ramesh ^a   Coss, Christopher C ^a   Hu, Kejiang ^a   He, Yali ^a   Wu, Zhongzhi ^a   Hong, Seoung Soo ^a   Hwang, Dong Jin ^a   Miller, Duane D ^a   Dalton, James T ^a  

^a GTx Inc   (United States)

Author keywords

Cancer; Cardiovascular disease; DPN; ER selective agonists; ERB 041; Estrogen receptor subtype ; Estrogen replacement therapy; Inflammation; MF 101; Nonsteroidal estrogens; PPT

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 4 HYDROXYTOREMIFENE; AUS 131; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOXAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA AGONIST; GENISTEIN; HORMONE RECEPTOR STIMULATING AGENT; MENERBA; METHOTREXATE; MF 101; OXIME DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENOL DERIVATIVE; PRINABEREL; PROGESTERONE AGONIST; RALOXIFENE; SULFONAMIDE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VG 101; WAY 070; WAY 202196; WAY 244; WAY 358;

ARTHRITIS; ASTHMA; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROHN DISEASE; DNA BINDING; DRUG BINDING; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIOSIS; GENOMICS; HUMAN; INFLAMMATION; IRRITABLE COLON; NEOPLASM; NONHUMAN; PATENT; PHARMACOPHORE; PNEUMONIA; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; VAGINA ATROPHY; VAGINAL DRYNESS; VASOMOTOR DISORDER;

ANIMALS; DRUG DELIVERY SYSTEMS; ESTROGEN RECEPTOR BETA; ESTROGENS; HUMANS; LIGANDS; PATENTS AS TOPIC;

EID: 77949878004     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003657164     Document Type: Review

References (199)

1. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-486
2. Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. FEBS Lett 2008;582(1):2-9
3. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240(4854):889-895
4. Segal S, Narayanan R, Dalton JT. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs 2006;15(4):377-387
5. Lofthouse S, Snibson K. Claims of current inhaled corticosteroid patents for treating asthma. Recent Pat Inflamm Allergy Drug Discov 2007;1(2):146-150
6. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann NY Acad Sci 1996;804:266-275
7. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92(3):1045-1052
8. Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol 2009;114(3):616-622
9. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006;132(Suppl 1):S17-26
10. Ottow E, Weinmann H. Nuclear Receptors as Drug Targets. Weinheim, Germany: Wiley-VCH; 2008
11. Dodds EC, Lawson W. Synthetic oestrogenic agents without a phenanthrene nucleus. Nature 1936;137:56
12. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Rec Prog Horm Res 1962;18:387-414
13. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;231(4742):1150-1154
14. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320(6058):134-139
15. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93(12):5925- 5930
16. Lubahn DB, Moyer JS, Golding TS, et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90(23):11162-11166
17. Couse JF, Curtis SW, Washburn TF, et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol 1995;9(11):1441-1454
18. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999;20(3):358-417
19. Curtis Hewitt S, Couse JF, Korach KS. Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2000;2(5):345-352
20. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006;116(3):561-570
21. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138(3):863-870
22. Shughrue PJ, Lane MV, Scrimo PJ, Merchenthaler I. Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 1998;63(10):498-504
23. Veeneman GH. Non-steroidal subtype selective estrogens. Curr Med Chem 2005;12(9):1077-1136
24. Nishihara E, Nagayama Y, Inoue S, et al. Ontogenetic changes in the expression of estrogen receptor alpha and beta in rat pituitary gland detected by immunohistochemistry. Endocrinology 2000;141(2):615-620
25. Shupnik MA. Oestrogen receptors, receptor variants and oestrogen actions in the hypothalamic-pituitary axis. J Neuroendocrinol 2002;14(2):85-94
26. Dupont S, Krust A, Gansmuller A, et al. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000;127(19):4277-4291
27. Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95(26):15677-15682
28. Shughrue PJ, Askew GR, Dellovade TL, Merchenthaler I. Estrogen-binding sites and their functional capacity in estrogen receptor double knockout mouse brain. Endocrinology 2002;143(5):1643-1650
29. Harris HA. Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol 2007;21(1):1-13
30. Windahl SH, Andersson G, Gustafsson JA. Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol Metab 2002;13(5):195-200
31. Sanchez-Criado JE, Martin De Las Mulas J, Bellido C, et al. Biological role of pituitary estrogen receptors ERalpha and ERbeta on progesterone receptor expression and action and on gonadotropin and prolactin secretion in the rat. Neuroendocrinology 2004;79(5):247-258
32. Prins GS, Birch L, Couse JF, et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 2001;61(16):6089-6097
33. Weihua Z, Makela S, Andersson LC, et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001;98(11):6330-6335
34. Cunha GR, Wang YZ, Hayward SW, Risbridger GP. Estrogenic effects on prostatic differentiation and carcinogenesis. Reprod Fertil Dev 2001;13(4):285-296
35. Ricke WA, McPherson SJ, Bianco JJ, et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. Faseb J 2008;22(5):1512-1520
36. McPherson SJ, Ellem SJ, Simpson ER, et al. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007;148(2):566-574
37. Norman BH, Dodge JA, Richardson TI, et al. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem 2006;49(21):6155-6157
38. Catley MC, Birrell MA, Hardaker EL, et al. Estrogen receptor beta: expression profile and possible anti-inflammatory role in disease. J Pharmacol Exp Ther 2008;326(1):83-88
39. Cvoro A, Tatomer D, Tee MK, et al. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 2008;180(1):630-636
40. Harris HA. Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential. Ernst Schering Found Symp Proc 2006;(1):149-161
41. Mewshaw RE, Edsall RJ Jr, Yang C, et al. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem 2005;48(12):3953-3979
42. Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003;144(10):4241-4249
43. Harris HA, Bruner-Tran KL, Zhang X, et al. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20(4):936-941
44. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000;2000(27):135-145
45. Hartman J, Lindberg K, Morani A, et al. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006;66(23):11207-11213
46. Wong NA, Malcomson RD, Jodrell DI, et al. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005;207(1):53-60
47. Forster C, Makela S, Warri A, et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 2002;99(24):15578-15583
48. Gilad LA, Tirosh O, Schwartz B. Phytoestrogens regulate transcription and translation of vitamin D receptor in colon cancer cells. J Endocrinol 2006;191(2):387-398
49. Motylewska E, Stasikowska O, Melen-Mucha G. The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett 2009;276(1):68-73
50. Zhang G, Liu X, Farkas AM, et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2009;23(2):146-156
51. Schrepfer S, Deuse T, Munzel T, et al. The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. Menopause 2006;13(3):489-499
52. Yu HP, Shimizu T, Choudhry MA, et al. Mechanism of cardioprotection following trauma-hemorrhagic shock by a selective estrogen receptor-beta agonist: up-regulation of cardiac heat shock factor-1 and heat shock proteins. J Mol Cell Cardiol 2006;40(1):185-194
53. Ba ZF, Chaudry IH. Role of estrogen receptor subtypes in estrogen-induced organ-specific vasorelaxation after trauma-hemorrhage. Am J Physiol Heart Circ Physiol 2008;295(5):H2061-7
54. Pelzer T, Loza PA, Hu K, et al. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation 2005;111(12):1492-1498
55. Otto C, Wessler S, Fritzemeier KH. Exploiting nongenomic estrogen receptor-mediated signaling for the Development of pathway-selective Estrogen receptor ligands. Ernst Schering Found Symp Proc 2006;(1):163-181
56. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007;27(5):691-700
57. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25(1):45-71
58. Madak-Erdogan Z, Kieser KJ, Kim SH, et al. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 2008;22(9):2116-2127
59. Ordonez-Moran P, Munoz A. Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 2009;8(11):1675-1680
60. Levin ER. Rapid signaling by steroid receptors. Am J Physiol Regul Integr Comp Physiol 2008;295(5):R1425-30
61. Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002;298(5594):843-846
62. Song RX, Fan P, Yue W, et al. Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr Relat Cancer 2006;13(Suppl 1):S3-13
63. Kumar R, Thompson EB. The structure of the nuclear hormone receptors. Steroids 1999;64(5):310-319
64. Claessens F, Gewirth DT. DNA recognition by nuclear receptors. Essays Biochem 2004;40:59-72
65. Rolland Y, Abellan van Kan G, Benetos A, et al. Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives. J Nutr Health Aging 2008;12(5):335-346
66. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001;29(14):2905-2919
67. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 2006;27(4):299-402
68. Ryan KJ. Editorial: cancer risk and estrogen use in the menopause. N Engl J Med 1975;293(23):1199-1200
69. Minutolo F, Bertini S, Granchi C, et al. Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta. J Med Chem 2009;52(3):858-867
70. Veeneman GH. Subtype-selective estrogens. In: Ottow E, Weinmann H, editor. Nuclear receptors as drug targets. Wiley-VCH; 2008. p. 71-87
71. Redden PR. Selective Estrogen Receptor Modulators. Expert Opin Ther Patents 2004;14(3):337-353
72. Ullrich JWaCPM. Estrogen receptor modulator review. Expert Opin Ther Patents 2006;16(5):559-572
73. Manas ES, Mewshaw RE, Harris HA, Malamas M S. Chapter 8: isoform specificity: the design of estrogen receptorbeta selective compounds. In: Hubbard RE, editor, Structure-based drug discovery: an overview. Royal Society of Chemistry Publishing; 2006. p. 219-250
74. Wyeth, Assignee. Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents. WO2004099122; 2004
75. Yang C, Edsall R Jr, Harris HA, et al. ERbeta ligands. Part 2: synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl- carbaldehyde oxime derivatives. Bioorg Med Chem 2004;12(10):2553-2570
76. Gutteridge JM, Quinlan GJ. Malondialdehyde formation from lipid peroxides in the thiobarbituric acid test: the role of lipid radicals, iron salts, and metal chelators. J Appl Biochem 1983;5(4-5):293-299
77. Shughrue PJ, Lane MV, Merchenthaler I. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study. Endocrinology 1997;138(12):5476-5484
78. Merchenthaler I, Funkhouser JM, Carver JM, et al. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998;30(3):307-316
79. Cuzzocrea S, Santagati S, Sautebin L, et al. 17beta-estradiol antiinflammatory activity in carrageenan-induced pleurisy. Endocrinology 2000;141(4):1455-1463
80. Zaulyanov LL, Green PS, Simpkins JW. Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in Vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol 1999;19(6):705-718
81. Prokai L, Oon SM, Prokai-Tatrai K, et al. Synthesis and biological evaluation of 17beta-alkoxyestra-1,3, 5(10)-trienes as potential neuroprotectants against oxidative stress. J Med Chem 2001;44(1):110-114
82. Poole AR, Coombs RR. Rheumatoid-like joint lesions in rabbits injected intravenously with bovine serum. Int Arch Allergy Appl Immunol 1977;54(2):97-113
83. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53(3):523-537
84. Dubal DB, Shughrue PJ, Wilson ME, et al. Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci 1999;19(15):6385-6393
85. Smirnoff P, Liel Y, Gnainsky J, et al. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999;11(6):255-264
86. Lundeen SG, Zhang Z, Zhu Y, et al. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001;78(2):137-143
87. Wyeth, Assignee. Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents. US7157491; 2007
88. Vu AT, Campbell AN, Harris HA, et al. ERbeta ligands. Part 6: 6H-Chromeno [4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett 2007;17(14):4053-4056
89. Wyeth, Assignee. (Hydroxyphenyl)-1H-indole- 3-carbaldehyde oxime derivatives as estrogenic agents. US20050059723; 2005
90. Meyers MJ, Sun J, Carlson KE, et al. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001;44(24):4230-4251
91. Kilbourn MR, Arduengo AJ, Park JT, Katzenellenbogen JA. Conformational analysis of nonsteroidal estrogens: The effect of conformer populations on the binding affinity of meso- and dl-hexestrol to the estrogen receptor. Mol Pharmacol 1981;19(3):388-398
92. Board of Trustees at the University of Illinois, assignee. Sulfonamides as selective estrogen receptor modulators. US20070021495; 2007
93. Board of Trustees of the University of Illinois, assignee. Estrogen receptor ligands. WO200019994; 2000
94. Coghlan RDF, Harris WF, Keith HA, et al., Assignee. Phenyl substituted thiophenes as estrogenic agents. US6835745; 2004
95. American Home Products Corporation, assignee. Bioassay for identifying estrogen receptor-beta/alpha selective modulators. WO2000037681; 2000
96. Harris H, Henderson R, Bhat R, Komm B. Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells. Endocrinology 2001;142(2):645-652
97. Novo Nordisk A/S, assignee. Identification of ligands by selective amplification of cells transfected with receptors. US5707798; 1998
98. Acadia Pharmaceuticals, Inc., assignee. Compounds with activity at estrogen receptor. US2005256210; 2005
99. Stauffer SR, Coletta CJ, Tedesco R, et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 2000;43(26):4934-4947
100. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002;143(11):4172-4177
101. Gardell LR, Hyldtoft L, Del Tredici AL, et al. Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist. Eur J Pharmacol 2008;592(1-3):158-159
102. Piu F, Cheevers C, Hyldtoft L, et al. Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist. Eur J Pharmacol 2008;590(1-3):423-429
103. Merck & Co., Inc., assignee. Estrogen receptor modulators. WO2002091993; 2002
104. Blizzard TA, Morgan JD II, Mosley RT, et al. 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett 2003;13(3):479-483
105. Muthyala RS, Sheng S, Carlson KE, et al. Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. J Med Chem 2003;46(9):1589-1602
106. Muthyala RS, Carlson KE, Katzenellenbogen JA. Exploration of the bicyclo[3.3.1]nonane system as a template for the development of new ligands for the estrogen receptor. Bioorg Med Chem Lett 2003;13(24):4485-4488
107. Zhou HB, Comninos JS, Stossi F, et al. Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure. J Med Chem 2005;48(23):7261-7274
108. Wyeth, Assignee. Substituted indenones as estrogenic agents. US6903238; 2005
109. Karo Bio AB, Assignee. 2-Phenyl indene derivatives useful as estrogen receptor ligands. WO2008043567; 2008
110. Wyeth, Assignee. Substituted 2-phenyl benzofurans as estrogenic agents. Patent US6774248 (2004)
111. Collini MD, Kaufman DH, Manas ES, et al. 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med. Chem Lett 2004;14(19):4925-4929
112. Astrazeneca AB, Assignee. Therapeutic benzimidazole compounds. patent WO2002046168; 2002
113. Astrazeneca AB, Assignee. Therapeutic compounds. WO2002051821; 2002
114. Wyeth, Assignee. Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents. US6960607; 2005
115. Wyeth, Assignee. Substituted benzoxazoles as estrogenic agents. US6794403; 2004
116. Wyeth, Assignee. Prodrug substituted benzoxazoles as estrogenic agents. US20060046968; 2006
117. Wyeth, assignee. Use of ER-beta selective ligands for treating acute lung injuries. US20080182872; 2008
118. Leventhal L, Brandt MR, Cummons TA, et al. An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain. Eur J Pharmacol 2006;553(1-3):146-148
119. Follettie MT, Pinard M, Keith JC Jr, et al. Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041. Endocrinology 2006;147(2):714-723
120. Malamas MS, Manas ES, McDevitt RE, et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem 2004;47(21):5021-5040
121. Pfizer, Inc., assignee. Benzimidazole compounds and their use as estrogen agonists/antagonists. US20040002524; 2004
122. De Angelis M, Stossi F, Carlson KA, et al. Indazole estrogens: highly selective ligands for the estrogen receptor beta. J Med Chem 2005;48(4):1132-1144
123. Japan Tobacco, Inc., assignee. Indole compounds and their medicinal use. JP2001122855; 2001
124. Pfizer, Inc., assignee. Indole compounds and their use as estrogen agonists/ antagonists. US20030220377; 2003
125. Laboratoire Theramex, assignee. Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents. WO2006040351; 2006
126. Eli Lilly and Company, assignee. Substituted benzopyrans as selective estrogen receptor-beta agonists. WO2004094401; 2004
127. Akzo Nobel NV, assignee. Chroman derivatives as estrogenic compounds. US2003069303; 2003
128. Bionovo, Inc., assignee. Composition for treatment of menopause. US20060222721; 2006
129. Cvoro A, Paruthiyil S, Jones JO, et al. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 2007;148(2):538-547
130. Stovall DW, Pinkerton JV. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women. Curr Opin Investig Drugs 2009;10(4):365-371
131. Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a Phase II clinical trial. Menopause 2009;16(3):458-465
132. Powell E, Xu W. Intermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers. Proc Natl Acad Sci USA 2008;105(48):19012-19017
133. Mersereau JE, Levy N, Staub RE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 2008;283(1-2):49-57
134. Bionovo, Inc., assignee. Liquiritigenin and derivatives as selective estrogen receptor beta agonists. WO2009002802; 2009
135. Bionovo, Inc., assignee. Estrogenic extracts of Asparagus conchinchinensis (lour.) merr of the Lilliaceae family and uses thereof. WO2009033025; 2009
136. Bionovo, Inc., assignee. Estrogenic extracts of Astragalus membranaceus Fisch.bge.var. mongolicus bge of the Leguminosae family and uses thereof. WO2009033099; 2009
137. Bionovo, Inc., assignee. Estrogenic extracts of Ligustrum lucidum and uses thereof. WO2009021196; 2009
138. Bionovo, Inc., assignee. Estrogenic extracts of Pueraria lobata willd, ohwi of the Leguminosae family and uses thereof. WO2009033103; 2009
139. Bionovo, Inc., assignee. Estrogenic extracts of Rheum palmatum L. of the Polyganaceae family and uses thereof. WO2009033105; 2009
140. Bionovo, Inc., assignee. Estrogenic extracts of Scuttelaria barbata D. don of the Labiatae family and uses thereof. WO2009033075; 2009
141. Universiteit Gent, assignee. Naringenin derivatives with selectivity on ERs. WO2007053915; 2007
142. Children's Hospital Medical Center (Cincinnati, OH) and Australian Health & Nutrition Assoc. Ltd (New South Wales, Australia), assignee. Compositions and products contining S-equol, and methods for their making. US7396855; 2008
143. Girindus America, Inc. (Cincinnati, OH) and Children's Hospital Medical Center (Cincinnati, OH), assignee. Method for enantioselective hydrogenation of chromenes. US7528267; 2009
144. Signal Pharmaceuticals, Inc., assignee. Compounds and methods for modulation of estrogen receptors. US6686351; 2004
145. AstraZeneca AB, assignee. Selective estrogen receptor-beta ligands. US7256201; 2007
146. Bristol-Myers Squibb Company, assignee. 3-Arylquinazolinone derivatives as selective estrogen receptor beta modulators. US7381730; 2008
147. Bristol-Myers Squibb Company, assignee. C5-substituted quinazolinone derivatives as selective estrogen receptor beta modulators. WO2006116401; 2006
148. Gungor T, Chen Y, Golla R, et al. Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem 2006;49(8):2440-2455
149. Bristol-Myers Squibb Company, assignee. 3-Aryl-hydoxybenzoxazines and 3,4-dihydro-3-arylbenzoxazines as selective estrogen receptor beta modulators. US7015219; 2006
150. Yang W, Wang Y, Ma Z, et al. Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists. Bioorg Med Chem Lett 2004;14(9):2327-2330
151. Wyeth, Assignee. Phenyl quinolines and their use as estrogenic agents. US20050009784; 2005
152. Wyeth, Assignee. Substituted phenyl naphthalenes as estrogenic agents. US6914074; 2005
153. Aventis Pharmaceutical, Inc., assignee. Use of certain phenyl-naphthyl compounds that do not have significant affinity to ER alpha or ER beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis. US20070225330; 2007
154. GTx, Inc., assignee. Nuclear receptor binding agents. WO2008091555; 2008
155. Richardson TI, Dodge JA, Wang Y, et al. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: combined A- and C-ring structure-activity relationship studies. Bioorg Med. Chem Lett 2007;17(20):5563-5566
156. Richardson TI, Dodge JA, Durst GL, et al. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. Bioorg Med Chem Lett 2007;17(17):4824-4828
157. Norman BH, Richardson TI, Dodge JA, et al. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. Bioorg Med Chem Lett 2007;17(18):5082-5085
158. Eli Lilly and Company, assignee. Substituted benzopyrans as selective estrogen receptor beta agonists. US6630508; 2003
159. Eli Lilly and Company, assignee. Substituted benzopyrans as selective estrogen receptor- beta agonists. WO2004094400; 2004
160. Eli Lilly and Company, assignee. Substituted benzopyrans as selective estrogen receptor-beta agonists. US7279499; 2007
161. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007;9(Suppl 1):S3-8
162. Eli Lilly and Company, assignee. Substituted tetralins as selective estrogen receptor-beta agonists. WO2006088716; 2006
163. Wilkening RR, Ratcliffe RW, Tynebor EC, et al. The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands. Bioorg Med Chem Lett 2006;16(13):3489-3494
164. Wilkening RR, Ratcliffe RW, Fried AK, et al. Estrogen receptor beta-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere. Bioorg Med. Chem Lett 2006;16(15):3896-3901
165. Parker DL, Jr., Meng D, et al. Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists. Bioorg Med Chem Lett 2006;16(17):4652-4656
166. Merck & Co., Inc., assignee. ER modulators. US7157604; 2007
167. Merck & Co., Inc., assignee. Estrogen receptor modulators. US7087599; 2006
168. Merck & Co., Inc., assignee. ERM's. WO2002041835; 2002
169. Merck & Co., Inc., assignee. Modulators of the estrogen receptor. WO2006062876; 2006
170. Merck & Co., Inc., assignee. Modulators of ER. WO2007089291; 2007
171. Merck & Co., Inc., assignee. ER modulators. US7151196; 2006
172. Merck, Assignee. Pyranoflavonoid compounds and their use as estrogen receptor modulators. WO2002058639; 2002
173. Wyeth, Assignee. Dibenzo chromene derivatives and their use as ERbeta selective ligands. US7157492; 2007
174. Wyeth, Assignee. Substituted 6H-dibenzo [c,h]chromenes as estrogenic agents. WO2003051863; 2003
175. Wyeth, Assignee. 6H-[1]benzopyraro [4,3-b]quinolines and their use as estrogenic agents. US20060052410; 2006
176. Wyeth, Assignee. Tetracyclic compounds as estrogenic ligands. US20060004087; 2006
177. Paruthiyil S, Cvoro A, Zhao X, et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One 2009;4(7):e6271
178. Nilsson S, Kuiper G, Gustafsson JA. ERbeta a novel estrogen receptor offers the potential for new drug development. Trends Endocrinol Metab 1998;9(10):387-395
179. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. Embo J 1999;18(17):4608-4618
180. Edsall RJ Jr, Harris HA, Manas ES, Mewshaw RE. ERbeta ligands. Part 1: the discovery of ERbeta selective ligands which embrace the 4-hydroxy-biphenyl template. Bioorg Med Chem 2003;11(16):3457-3474
181. Vu AT, Cohn ST, Manas ES, et al. ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett 2005;15(20):4520-4525
182. McDevitt RE, Malamas MS, Manas ES, et al. Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett 2005;15(12):3137-3142
183. Manas ES, Unwalla RJ, Xu ZB, et al. Structure-based design of estrogen receptor-beta selective ligands. J Am Chem Soc 2004;126(46):15106-15119
184. Richardson TI, Norman BH, Lugar CW, et al. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold. Bioorg Med Chem Lett 2007;17(13):3570-3574
185. Chesworth R, Wessel MD, Heyden L, et al. Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett 2005;15(24):5562-5566
186. Schopfer U, Schoeffter P, Bischoff SF, et al. Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes. J Med. Chem 2002;45(7):1399-1401
187. De Angelis M, Stossi F, Waibel M, et al. Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites. Bioorg Med Chem 2005;13(23):6529-6542
188. Blizzard TA, Gude C, Chan W, et al. Bridged androstenediol analogs as ER-beta selective SERMs. Bioorg Med Chem Lett 2007;17(10):2944-2948
189. Blizzard TA, Gude C, Morgan JD II, et al. Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett 2007;17(22):6295-6298
190. Blizzard TA, Gude C, Morgan JD II, et al. Androstenediol analogs as ER-beta-selective SERMs. Bioorg Med Chem Lett 2006;16(4):834-838
191. Sun W, Cama LD, Birzin ET, et al. 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett 2006;16(6):1468-1472
192. Harris HA. The unexpected science of estrogen receptor-beta selective agonists: a new class of anti-inflammatory agents? Nucl Recept Signal 2006;4:e012
193. Walf AA, Koonce CJ, Frye CA. Estradiol or diarylpropionitrile decrease anxiety-like behavior of wildtype, but not estrogen receptor beta knockout, mice. Behav Neurosci 2008;122(5):974-981
194. Walf AA, Koonce CJ, Frye CA. Adult female wildtype, but not oestrogen receptor beta knockout, mice have decreased depression-like behaviour during pro-oestrus and following administration of oestradiol or diarylpropionitrile. J Psychopharmacol 2009;23(4):442-450
195. Motylewska E, Stasikowska O, Melen-Mucha G. The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett 2009;276(1):68-73
196. McCarty MF, Barroso-Aranda J, Contreras F. Genistein and phycocyanobilin may prevent hepatic fibrosis by suppressing proliferation and activation of hepatic stellate cells. Med Hypotheses 2009;72(3):330-332
197. Liu F, Day M, Muniz LC, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci 2008;11(3):334-343
198. Meltser I, Tahera Y, Simpson E, et al. Estrogen receptor beta protects against acoustic trauma in mice. J Clin Invest 2008;118(4):1563-1570
199. Merlo S, Frasca G, Canonico PL, Sortino MA. Differential involvement of estrogen receptor alpha and estrogen receptor beta in the healing promoting effect of estrogen in human keratinocytes. J Endocrinol 2009;200(2):189-197